ML signed the awaited deal for its inhaler drug last week. expect the announcement in a week.

Fully agree with hangon
pay by preformance only, shareholders would welcome
high saleries if they were being rewarded by an increase
in profit and share price, but as usual shareholders get
stuffed sideways with no redress on the board it would seem.
Then when they ousted for non preformance they expect a kings
ransom for there trouble meanwhile shareholders have to suffer
for years just to recoup thier investment as is the case with ML

regards - long term investor still 57% down - pissed right off.
Will it ever bear any good news or will it come to shareholders
to stump up yet more millions just to pay the boards wages.

M.L. Laboratories PLC
03 March 2005

Embargoed Until 0700 3 March 2005


ML Laboratories PLC
('ML' or 'the Company')

Board Restructuring

The employment of Stuart Sim, ML's Executive Chairman, has been terminated by
the Board, and Mr Sim has ceased to be a director, with immediate effect.

The Company also announces that Mr Ian Kent and Mr Kieran Murphy have joined the
board as Executive Chairman and Chief Executive respectively.

Mr Kent was a director of Biofocus PLC from 2001 to 2003 and of Vernalis PLC
from 2002 to 2003. Mr Murphy was a director of Cobequid Life Sciences, a public
company quoted in Canada, from 1998 to 2000.

There are no other details to be disclosed pursuant to paragraphs 16.4(a) and
(b) of the Listing Rules.

- Ends -

Enquiries:

ML Laboratories PLC
Ian Kent, Executive Chairman 01223 303309
Peter Shennan, Finance Director 01925 844700

Weber Shandwick Square Mile
Kevin Smith 020 7067 0700



This information is provided by RNS
The company news service from the London Stock Exchange

Its Clarke Kent they need.

I think this is now the start of good things. The markets normally react favourably with a new appointment. Think I will top up again.

Glad I topped up. up 15% this morning.:)

I've held these for 18 months
Looks like the city likes the new management - up a further 9% today.
More positive news in the pipeline, i think my break even of 32p isnt too far away and from there who knows
Good luck

Chart looking better than it has in a very long time.

Good luck.

Rumours & Shakers 4/3/2005

Shares in ML Labs rose 2p to 23.25p today after specialist small cap website WatsHot.com reported market talk that someone might be stake-building in the healthcare technology group. It said that Thursday's announcement from the company that its chairman and chief executive had finally been ousted was expected - so why the large number of trades after the fact? Well, the word on the street is that someone has been making offers to big holders of the stock to purchase the shares at a premium to the current market price. Market talk suggests that a bidder is stake-building on the sidelines ahead of launching a full offer for the group.

We need some more news to keep this one going. LOL

M.L. Laboratories PLC
15 March 2005


Embargoed until 0700 GMT 15 March 2005

ML Laboratories PLC
('ML' or 'the Company')

ML's CLICKHALER APPROVED IN JAPAN

ML Laboratories plc (MLB.L) announced today that its respiratory subsidiary,
Innovata Biomed ('IB') has received news from its licensee Otsuka Pharmaceutical
Co, Ltd. that its Meptin Clickhaler product has been approved in Japan.

Under the terms of its Agreement with Otsuka, IB will receive a milestone
payment on approval. Clickhalers will be supplied to Otsuka on a commercial
basis. It is anticipated that Meptin Clickhaler will be introduced to the market
later in 2005.

Commenting for IB, Paul Ballington, Managing Director noted, 'This is a
significant event for IB, and demonstrates how products incorporating our
technologies can be successfully developed in the hands of our licensees. Otsuka
is a powerful competitor in the Japanese asthma market and a valuable licensee
for Clickhaler.'
- ends -

Enquiries:
Innovata Biomed Limited
Paul Ballington, Managing Director 01727 837341

www.innovata-biomed.com


Weber Shandwick Square Mile 020 7067 0700
Kevin Smith / Yvonne Alexander

Notes to Editors

ML Laboratories plc

ML is a pharmaceutical product development company with a track record of
successful clinical development, regulatory approval and licensing of
pharmaceutical products and which has a pipeline of future products targeted at
specialist markets. ML's activities are supported by a growing income stream
from marketed products it has successfully developed and licensed to other
pharmaceutical companies, which include Baxter, Shire, Celltech, Otsuka and
Pliva.

New therapeutic products in clinical development include a phosphate binder to
assist the management of kidney failure, treatments for prostate cancer and skin
cancer and a pain management compound. ML's technologies include unique
mechanisms for use in the discovery and manufacture of biotechnology products.

In addition ML provides inhaled drug delivery solutions to the global
pharmaceutical industry through its dedicated respiratory subsidiary Innovata
Biomed (IB).

Innovata Biomed

IB is a leading independent provider of inhaled drug delivery technologies to
the pharmaceutical industry. IB's proven delivery technologies are available for
proof of principle testing and as 'fast-to-market' drug delivery solutions.



This information is provided by RNS
The company news service from the London Stock Exchange

If someone is going to make a bid for this company they better do it soon before too much good news comes out.DYOR

it's about time we had some positive
news we've waited long enough,
lets hope it has been worth waiting for
and reflects in the sp
all the best

HUSTLER

No buyers here. Good news and they all sell !!!

This stock is realy spooking me Troys
years of crap then good news and everyone sells
can only hope the new management shakes it by the
throat over time. Just hope they don't come back
to investors for yet more funding.

regards HUSTLER

ML Laboratories PLC (the 'Company')

Notification of Major Interests in Shares

Section 198 to 202 Companies Act 1985

The Company received a notification today from AVIVA plc on behalf of itself and
Morley Fund Management Limited informing it that following share purchases of
1,000,000 shares on 16 March 2005, they have in interest in 23,392,806 shares
representing 10.23% of the Company's issued ordinary share capital.

18 March 2005

M.L. Laboratories PLC
22 March 2005


For Immediate Release 22 March 2005

ML Laboratories plc



Marketing Approvals Received for Two Separate Asthma Compounds in First European
Market



ML Laboratories plc (MLB.L) has received news from its licensing partner that
its innovative dry powder inhaler, Clickhaler(R), has been granted two marketing
approvals in its first European market for use with budesonide and formoterol
respectively, two widely-prescribed asthma therapies. This is the first country
in Europe to approve these two Clickhaler products and applications in other
European markets are progressing.



The budesonide and formoterol Clickhaler products were licensed by ML to an
undisclosed major pharmaceutical partner in September 2002. Under the terms of
this agreement, ML receives milestone payments on receipt of marketing
approvals, followed by further milestones on product launches and double digit
royalties on sales.



Sales of comparable budesonide products in Europe total 200 million while the
European market for comparable formoterol products is estimated at more than
100 million. Both Clickhaler products will be launched at the earliest
opportunity.



Clickhaler products are now approved in one or more European countries for
salbutamol, beclomethasone, budesonide and formoterol, with the Meptin
Clickhaler (Otsuka's procaterol) recently approved in Japan.



Paul Ballington, Director of Marketing and Business Development, commented:



'Clickhaler has now been approved with a number of asthma treatments, each
representing a substantial market opportunity. The European markets for both
budesonide and formoterol are predominantly in dry powder delivery devices and
we believe that Clickhaler's ease of use and reliability will enable it to gain
a significant share of these markets.'





Contacts:


ML Laboratories plc Tel: +44 (0)1727 837 341
Paul Ballington
Managing Director of Innovata Biomed

Financial Dynamics Tel: +44 (0)7747 602 739 / (0) 20 7831 3113
David Yates / Sarah MacLeod





Notes to Editors



ML Laboratories plc

ML operates through two divisions, both focused on the development of high value
pharmaceutical products - Innovata Biomed, the Group's respiratory division, and
ML Pharmaceuticals, a pharmaceutical product development business.



Innovata Biomed (IB) is a leading independent provider of inhaled drug delivery
technologies to the global pharmaceutical industry, formulating dry powders and
developing proprietary inhaler systems through to full industrialisation. IB's
proven delivery technologies are available for proof-of-principle testing and as
fast-to-market drug delivery solutions. It has a number of respiratory products
both in development and marketed by pharmaceutical company licensees including
Celltech, Otsuka and Pliva.



ML's pharmaceutical product development division, ML Pharmaceuticals, contains
both marketed products and new therapeutics in clinical development. Marketed
products include Extraneal for the treatment of renal failure, which has been
licensed to Baxter, and Adept for the reduction of adhesions in abdominal
surgery, which is marketed by Shire Pharmaceuticals in Europe. New therapeutic
products in development include Alpharen, a phosphate binder to assist the
management of kidney failure, treatments for prostate and skin cancer and a pain
management compound.


This information is provided by RNS
The company news service from the London Stock Exchange

Does any one know what the milestone payments are?

LONDON (AFX) - Pharmaceuticals group ML Laboratories PLC said its licensing partner for the Clickhaler dry powder inhaler, which it hasn't named, has announced the inhaler has won approval in the Netherlands for use with asthma treatments budesonide and formoterol.

The group said this is the first country in Europe to approve these two Clickhaler products and added that applications in other European markets are progressing.

The budesonide and formoterol Clickhaler products were licensed out by ML to an undisclosed 'major pharmaceutical partner' in September 2002. ML gets milestone payments on receipt of marketing approvals and then again on product launches, together with royalties on sales.

ML said sales of comparable budesonide products in Europe total are worth 200 mln stg while the European market for comparable formoterol products is estimated at some 100 mln stg.

The company said Clickhaler products are now approved in one or more European countries for use with salbutamol and beclomethasone as well as those announced today.

newsdesk@afxnews.com

cw

ML Laboratories plc
Appointment of Advisers


The Board of ML Laboratories plc is pleased to announce the appointment of new
advisers. Code Securities Limited is appointed as Financial Adviser and Broker
to the Company, Jones Day is appointed as Legal Adviser and Financial Dynamics
is appointed as Financial PR adviser. All appointments are effective
immediately.

M.L. Laboratories PLC
22 March 2005

Letter to: ML Laboratories PLC
Dated: 21 March 2005

ML LABORATORIES PLC (THE 'COMPANY') - SEDOL 0555470

This notification supersedes our previous notification to you dated 17 March
2005 and is prompted by purchases totalling 2,500,000 on 18 March 2005.

This notification relates to issued ordinary shares of GBP0.01 each in the
capital of the Company (the 'shares') and is given in fulfilment of the
obligations imposed by sections 198 to 202 of the Companies Act 1985 (the
'Act').

1. Notification on behalf of Morley Fund Management Limited (a subsidiary of
Aviva plc).

1.1 We hereby notify you on behalf of Morley Fund Management Limited that
immediately after the time when the obligation to make this notification
arose Morley Fund Management Limited were interested in 26,392,806 shares.

1.2 The identity of the registered holders of the shares to which this
notification relates and the number of shares held by each of them are set
out in the Appendix below: Morley Fund Management Limited.

2. Notification on behalf of Aviva plc.

2.1 We hereby notify you on behalf of Aviva plc that immediately after the
time when the obligation to make this notification arose Aviva plc were
interested in 26,392,806 shares giving the Aviva group a total percentage
interest in the shares of 11.54%.

2.2 The identity of the registered holders of the shares to which this
notification relates and the number of shares held by each of them are set
out in the Appendix below: Aviva plc.

From: Aviva PLC


APPENDIX: MORLEY FUND MANAGEMENT LIMITED

REGISTERED HOLDERS NUMBER OF SHARES HELD
BNY Norwich Union Nominees Ltd 845,163 (Material)
Chase GA Group Nominees Ltd 4,656,093 (Material)
CUIM Nominee Ltd 1,506,596 (Material)
Chase Nominees Ltd 5,300,000
Credit Agricole Indosuez 1,700,000
Vidacos Nominees Ltd 12,384,954


TOTAL PERCENTAGE INTEREST OF MORLEY FUND MANAGEMENT LIMITED: 11.54%

ISSUED SHARE CAPITAL ON WHICH THIS NOTIFICATION IS BASED: 228,710,703


APPENDIX: AVIVA PLC

REGISTERED HOLDERS NUMBER OF SHARES HELD
BNY Norwich Union Nominees Ltd 845,163 (Material)
Chase GA Group Nominees Ltd 4,656,093 (Material)
CUIM Nominee Ltd 1,506,596 (Material)
Chase Nominees Ltd 5,300,000
Credit Agricole Indosuez 1,700,000
Vidacos Nominees Ltd 12,384,954


TOTAL PERCENTAGE INTEREST OF AVIVA PLC: 11.54%

ISSUED SHARE CAPITAL ON WHICH THIS NOTIFICATION IS BASED: 228,710,703



This information is provided by RNS
The company news service from the London Stock Exchange